{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-100550","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2024-08-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.608968+00:00","generated_at":"2026-05-31T07:42:01.076386+00:00","sec_items":["1.01","3.02","3.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Revelation Biosciences raises ~$3.8M via warrant exercises; issues new warrants","bullets":["Class D warrant holders exercise 2,548,060 shares at reduced price of $1.50/share, gross proceeds ~$3.8M.","New Inducement Warrants issued to purchase up to 5,096,120 shares at $1.00/share, exercisable for 5 years.","Net proceeds to fund GEM-AKI, GEM-CKD, GEM-PSI clinical trials and working capital.","Roth Capital Partners paid ~$267,546 advisory fee; exercise prices of certain Class C/D warrants adjusted to $1.00."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-100550","json":"https://secwatch.observer/filing/0000950170-24-100550.json","markdown":"https://secwatch.observer/filing/0000950170-24-100550.md","text":"https://secwatch.observer/filing/0000950170-24-100550.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024100550/0000950170-24-100550-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024100550/revb-20240821.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:42:01.076386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}